Table 4.
Emergent adverse events during study therapies
| New symptom or finding | Testosterone, 5 g/d
|
Testosterone, 10 g/d
|
P value* | |||||
|---|---|---|---|---|---|---|---|---|
| GH 0 (n = 19) Group A | GH 3 μg (n = 19) Group B | GH 5 μg (n = 20) Group C | GH 0 (n = 20) Group D | GH 3 μg (n = 17) Group E | GH 5 μg (n = 17) Group F | |||
| Large joint pain or knee swelling | 40 (36%)a | 4 | 6 | 8 | 12 | 6 | 4 | 0.16 |
| Pretibial or ankle edema | 39 (35%) | 6 | 7 | 10 | 6 | 4 | 6 | 0.68 |
| General aching or muscle pains | 33 (29%) | 6 | 7 | 2 | 3 | 7 | 8 | 0.07 |
| New skin rash (local/general) or bruises | 26 (19%) | 4 | 3 | 3 | 4 | 6 | 6 | 0.54 |
| Transient new cough/nasal congestion | 17 (15%) | 0 | 5 | 3 | 3 | 2 | 4 | 0.21 |
| Back pain | 14 (13%) | 0 | 3 | 1 | 3 | 5 | 3 | 0.11 |
| Transient hot flashes after treatment | 13 (12%) | 1 | 2 | 4 | 3 | 1 | 2 | 0.77 |
| Breast engorgement or nipple pain | 16 (14%) | 2 | 1 | 0 | 5 | 3 | 5 | 0.051b |
| Hand or wrist stiffness or pain | 8 (7%) | 1 | 4 | 1 | 1 | 1 | 0 | 0.32 |
| Mean ± sd | ||||||||
| Change in AUA score | n/a | 0.3 ± 3.4 | 1.0 ± 5.0 | 0.2 ± 2.2 | 2.2 ± 4.4 | −0.2 ± 3.6 | 1.2 ± 5.0 | 0.50 |
AUA, American Urological Association.
a
Total number with symptom.
b
P = 0.006 by Fisher’s exact test comparing 58 subjects receiving 5 g vs. 54 subjects receiving 10 g testosterone daily.